Sjogren's Syndrome
Welcome,         Profile    Billing    Logout  
 97 Companies   25 Products   25 Products   20 Mechanisms of Action   184 Trials   8296 News 


«12...89101112131415161718...145146»
  • ||||||||||  Review, Journal:  Extranodal Rosai-Dorfman disease manifesting as Sj (Pubmed Central) -  Apr 21, 2024   
    This is the first reported case of RDD presenting with SS in combination with panuveitis and HP. Although RDD is rarely diagnosed in young patients, interdisciplinary collaboration is essential to prevent a delayed diagnosis.
  • ||||||||||  Review, Journal:  Acute calcareous corneal degeneration in a patient with chronic graft-versus-host disease. (Pubmed Central) -  Apr 19, 2024   
    Calcareous corneal degeneration is a type of calcium deposition that can be secondary to chronic ocular inflammation or dry eye, but there are few cases reported of acute calcareous corneal degeneration and recurrent perforation in cGVHD. Abbreviations: GVHD = Chronic graft-versus-host disease, aGVHD = Acute graft-versus-host disease, cGVHD = Chronic graft-versus-host disease, KCS = Keratoconjunctivitis sicca, PKP = Penetrating keratoplasty, AMT = Amniotic membrane transplantation, PRGF = Plasma rich in growth factors, OD = Right eye, OS = Left eye.
  • ||||||||||  Review, Journal:  The role of Epstein-Barr virus in autoimmune and autoinflammatory diseases. (Pubmed Central) -  Apr 18, 2024   
    Research on therapeutic agents and vaccines for EBV has been stagnant for a long number of years until recent advances shed light on potential therapeutic targets. The implications of EBV in autoimmunity underscore the importance of developing targeted therapeutic strategies and, potentially, vaccines to mitigate the autoimmune burden associated with this ubiquitous virus.
  • ||||||||||  venanprubart (LY3361237) / Eli Lilly
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome (clinicaltrials.gov) -  Apr 17, 2024   
    P2,  N=0, Withdrawn, 
    Recruiting --> Completed | Trial completion date: Dec 2040 --> Apr 2024 | Trial primary completion date: Aug 2025 --> Apr 2024 N=12 --> 0 | Trial completion date: Dec 2025 --> Jan 2028 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2025 --> Jan 2027
  • ||||||||||  Proleukin low dose (aldesleukin low dose) / ILTOO
    Journal:  The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial. (Pubmed Central) -  Apr 17, 2024   
    N=12 --> 0 | Trial completion date: Dec 2025 --> Jan 2028 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2025 --> Jan 2027 Tregs stimulation by IL-2LD is a promising therapeutic strategy and IL-2LD holds considerable promise for integration into combinatorial therapeutic approaches.
  • ||||||||||  venlafaxine / Generic mfg., pilocarpine / Generic mfg., alprazolam / Generic mfg.
    Journal:  A relatively rare traditional Chinese medicine pattern of primary Sj (Pubmed Central) -  Apr 16, 2024   
    Tregs stimulation by IL-2LD is a promising therapeutic strategy and IL-2LD holds considerable promise for integration into combinatorial therapeutic approaches. This case report demonstrates that TCHM can effectively treat Primary Sj
  • ||||||||||  Journal:  The immunoregulatory effects of total glucosides of paeony in autoimmune diseases. (Pubmed Central) -  Apr 16, 2024   
    Moreover, TGP has been applied in the clinical treatment of various AIDs with satisfactory therapeutic outcomes and minor side effects. Thus, available studies have demonstrated that TGP and its bioactive constituents exhibit anti-inflammatory and immunomodulatory functions and may have extensive applications in the treatment of AIDs.
  • ||||||||||  sirolimus / Generic mfg.
    Journal:  Rapamycin can alleviate the submandibular gland pathology of Sj (Pubmed Central) -  Apr 11, 2024   
    Maladaptive activation of autophagy and cGAS-STING signaling pathway are central contributors to the SG pathogenesis of pSS patient. Regulating autophagy by rapamycin may be a possible treatment for Sj
  • ||||||||||  Journal:  Integrated analysis of m6A regulator-mediated RNA methylation modification patterns and immune characteristics in Sj (Pubmed Central) -  Apr 10, 2024   
    Our findings not only illuminate the significant correlation between m6A modification and the immune microenvironment in SS but also lay the groundwork for a deeper understanding of m6A regulatory mechanisms. More importantly, the identification of these key regulators and hub genes opens new avenues for the diagnosis and treatment of SS, presenting potential targets for therapeutic intervention.
  • ||||||||||  Journal:  CD4 T cell-secreted IFN-? in Sj (Pubmed Central) -  Apr 8, 2024   
    Our findings indicate that CD4 T cell-secreted IFN-? in SS induces SGECs' ferroptosis and inhibits AQP5 expression.
  • ||||||||||  Journal:  Sj (Pubmed Central) -  Apr 7, 2024   
    This study does not provide evidence to support the assertion that SS has a conclusive impact on the risk of PD, which contradicts numerous existing observational reports. Further investigation is necessary to determine the possible mechanisms behind the associations observed in these observational studies.
  • ||||||||||  Journal:  Mixed connective tissue disease and its management (Pubmed Central) -  Apr 7, 2024   
    In this review, we describe the clinical features and the potential complications of this complex disease, often wrongly disregarded as benign. We will also emphasize the recommended follow-up exams and address treatment, which is currently lacking formal recommendations.
  • ||||||||||  azathioprine / Generic mfg., ursodeoxycholic acid / Generic mfg.
    Journal:  Unprecedented complexity of six coexisting autoimmune diseases: A case report. (Pubmed Central) -  Apr 7, 2024   
    This patient presented with six concurrent distinct autoimmune disorders, categorizing this case as a type two multiple autoimmune syndrome. The identification of antisynthetase syndrome notably distinguishes this case.
  • ||||||||||  Journal, IO biomarker:  Clinicopathological features of Sjogren's syndrome complicated with liver injury (Pubmed Central) -  Apr 5, 2024   
    The inflammatory lesions of SS patients with autoimmune liver disease are the most serious, and the inflammatory lesions of SS patients with non-alcoholic fatty liver disease and non-specific inflammation are mild. Comprehensive analysis of liver histopathologic changes and laboratory findings is helpful for the diagnosis of SS complicated with different types of liver injury.
  • ||||||||||  Review, Journal:  What can patients tell us in Sj (Pubmed Central) -  Apr 4, 2024   
    The inclusion of PROMs is important for the success of such approaches. In this review we discuss the opportunities of using PROMs in understanding the pathogenesis of and therapeutic development for SS.
  • ||||||||||  Journal:  Mucosa-associated lymphoid tissue lymphoma at the parotid gland. (Pubmed Central) -  Apr 3, 2024   
    The patient was successfully treated with surgical excision with chemotherapy and remained disease-free at the 10-year follow-up. Since it was rare in the head and neck region, we present this case.
  • ||||||||||  dazodalibep (HZN-4920) / Amgen
    Enrollment open:  HZNP-DAZ-303: A Safety and Efficacy Study of Dazodalibep in Participants With Sj (clinicaltrials.gov) -  Apr 2, 2024   
    P3,  N=435, Recruiting, 
    Patients with better scores on facilitators and lower scores on barriers exhibited higher physical activity levels (p. Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Evaluation of Event-Related Potentials in Somatic Diseases - Systematic Review. (Pubmed Central) -  Apr 2, 2024   
    Event-related potential (ERP) methodology allows for monitoring neurocognitive processes and thus can provide a valuable window into these cognitive processes that are influenced, or brought about, by somatic disorders. The current review aims to present published studies on the relationships between somatic illness and brain function as assessed with ERP methodology, with the goal to discuss where this field of study is right now and suggest future directions.
  • ||||||||||  Preclinical, Journal:  Regulation of STAT1 and STAT4 Expression by Growth Factor and Interferon Supplementation in Sj (Pubmed Central) -  Apr 1, 2024   
    EGF/Interferon related pathways might be targeted to regulate STAT1 and STAT4 expression in salivary gland epithelial cells. Further investigation is required learn how to better target the Janus kinases/signal transducer and activator of transcription proteins (JAK/STAT) pathway-mediated inflammatory response in Sj
  • ||||||||||  New trial:  UltraSj (clinicaltrials.gov) -  Apr 1, 2024   
    P=N/A,  N=800, Recruiting, 
  • ||||||||||  New trial:  Rheumatology Diet Study (clinicaltrials.gov) -  Apr 1, 2024   
    P=N/A,  N=500, Recruiting,